BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Volcano Corporation Announces the Introduction of the Eagle Eye(R) Platinum Digital IVUS Catheter at the 20th PCI Live Demonstration Course in Kurashiki; Cleared for Use in Japan


3/4/2011 8:05:39 AM

SAN DIEGO, March 4, 2011 /PRNewswire/ -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it received clearance to market the Eagle Eye® Platinum digital IVUS catheter in Japan, and will introduce the device at the 20th PCI Live Demonstration Course in Kurashiki, which starts on March 3rd. This state-of-the-art catheter offers all of the benefits of the predecessor Eagle Eye® Gold catheter, plus improved deliverability and the convenience of additional radiopaque markers. Full market release of Eagle Eye® Platinum in Japan is expected in the second quarter of 2011.

"Volcano is thrilled to offer our most advanced digital IVUS catheter to the largest and most developed IVUS market in the world," commented David Sheehan, President of the IVUS and FM Business Units at Volcano Corporation. "Since the catheter's release in the US and Europe, customers have been impressed with its deliverability through tortuous anatomy and complex lesions, and have appreciated the ability to more accurately perform angiographic lesion length assessments by using the integrated radiopaque markers instead of taking the time to use a separate pullback device. We are expecting the strong interest that Japanese physicians have shown for the Eagle Eye® Platinum catheter to carry over into their clinical experience as well."

"In Japan, physicians are tackling increasingly complex and challenging PCI," added Junichi Osawa, President and Managing Director of Volcano Japan. "The more tapered tip design of the Eagle Eye Platinum catheter, with lower entry profile and new GlyDx® hydrophilic coating, facilitates guidance of CTO procedures, and the smoother lower profile catheter transitions improve delivery through smaller guides. This can help facilitate radial access, an approach common in Japan and growing elsewhere in the world due to reduced bleeding complications."

About Eagle Eye® Platinum

The Eagle Eye® Platinum is the third generation of catheters in the Eagle Eye® product line. Eagle Eye® catheters have been used in over 500,000 procedures worldwide. Like Eagle Eye® Gold, the Eagle Eye® Platinum catheter offers fast, plug-and-play functionality as well as grayscale IVUS, VH® IVUS, and ChromaFlo® imaging modalities.

About Volcano Corporation

Volcano Corporation (NASDAQ: VOLC) is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Our products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information, using sound and light as the guiding elements. Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together. For more information, visit the company's website at www.volcanocorp.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered "forward-looking statements." Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause Volcano's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include competition, the pace and extent of market adoption of the Eagle Eye® Platinum in Japan, unexpected new data, safety and technical issues,, and market conditions. These and additional risks and uncertainties are more fully described in Volcano's filings made with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made. Volcano disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

SOURCE Volcano Corporation



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES